 |  | | Investor Relations Home | Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials.
Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem. | | |
|
| Date | Title | | | 01/24/12 | Oramed Pharmaceuticals Granted Australian Patent for Important Part of the Company's Core Technology in Oral Delivery of Proteins|
JERUSALEM, January 24, 2012 /PRNewswire/ --
Marking a major milestone for the Company, Oramed Pharmaceuticals Inc. (OTCBB: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has received approval for a key patent by the Australian Patent Office. The patent covers an important part of the Company's core technology which allows for the oral delivery of peptides. Oramed's portfolio now consists of one issued patent and 34 patents pending for its... |
|  | | 01/10/12 | Oramed Pharmaceuticals Files US Patent Application for Combination Oral Treatment of Diabetes| Oral treatment can increase patient compliance in the estimated $15 billion US market
JERUSALEM, January 10, 2012 /PRNewswire/ --
Oramed Pharmaceuticals Inc. (OTCBB:ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has filed a provisional patent application with the United States Patent and Trademark Office for a combination therapy of its lead compound, ORMD-0801 in combination with its oral exenatide formulation, ORMD-0901. There is no su... |
| | | 10/25/11 | Oramed Pharmaceuticals Chosen to Present at the Diabetes Technology Meeting (October 27-29, 2011; San Francisco, CA)| JERUSALEM, October 25, 2011 /PRNewswire via COMTEX/ --Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that its work entitled "Evaluation of the Safety and Efficacy of Two Oral Insulin Formulations in Healthy Volunteers" will be presented at the Eleventh Annual Meeting of the Diabetes Technology Society, to be held in San Francisco, California.
"The selection of Oramed as one of the companies to present at the D... |
| | | 09/27/11 | Oramed Pharmaceuticals Announces Successful Phase 1 Clinical Trial Results for EnteraBio| JERUSALEM, September 27, 2011 /PRNewswire via COMTEX/ --Oramed Pharmaceuticals Inc. (OTC BB: ORMP) (http://www.oramed.com), a developer of oral delivery systems, announced that EnteraBio Ltd. recently reported successful Phase 1 clinical trial results. The Phase 1 data supports the continued development of Entera's oral osteoporosis drug.
Entera's IP was out-licensed from Oramed in 2010 and Oramed is entitled to 3% royalties plus a small holding in the company according to the agreement.
... |
| | | 09/15/11 | Oramed Pharmaceuticals Chosen to Present at the 8th Annual Israel Strategic Partner and Venture Conference on September 22, 2011| JERUSALEM, September 15, 2011 /PRNewswire via COMTEX/ --Oramed Pharmaceuticals Inc. (OTC BB: ORMP.OB) (http://www.oramed.com), a developer of oral delivery systems, announced today that Ehud Arbit, M.D., the Director of R&D at Oramed, is scheduled to present at the 8th Annual Israel Strategic Partner and Venture Conference. The conference will be held at the Bristol-Myers Squibb Pharmaceutical Research Institute in Princeton, NJ on September 22, 2011.
Dr Arbit is scheduled to speak on T... |
| |
|
|
| | There are currently no events scheduled. |
|
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. |
|
|
|
